Table 2.

Association of type and duration of hormone therapy (HT) use with fatal breast cancer. Odds Ratios (OR) and 95% confidence intervals (95CI). Women’s CARE Study, 1994–1998

		N cases/controls	OR (95CI)
Never Any HT		122 / 717	1.0 ref cat
Only CHT vs never any use of HT	Former, <3yr	8 / 78	.68 (.31, 1.46)
	Current, <3yr	12 / 136	.67 (.35, 1.30)
	Former, 3+ yr	2 / 16	1.02 (.23, 4.59)
	Current, 3+ yr	24 / 250	.83 (.50, 1.38)
Any CHT vs never any use of HT*	Former, <3yr	18 / 189	.72 (.42, 1.23)
	Current, <3yr	19 / 166	.95 (.54, 1.66)
	Former, 3+ yr	4 / 75	.47 (.17, 1.34)
	Current, 3+ yr	32 / 301	.94 (.59, 1.48)
Only ET vs never any use of HT	Former, <3yr	24 / 176	.90 (.55, 1.47)
	Current, <3yr	15 / 122	.87 (.47, 1.60)
	Former, 3+ yr	9 / 57	1.11 (.51, 2.41)
	Current, 3+ yr	35 / 416	.69 (.44, 1.09)
Any ET vs never any use of HT†	Former, <3yr	35 / 249	.97 (.64, 1.48)
	Current, <3yr	18 / 164	.82 (.46, 1.44)
	Former, 3+ yr	15 / 99	1.20 (.65, 2.22)
	Current, 3+ yr	42 / 510	.70 (.45, 1.07)
Any HT (CHT or ET) vs never any HT‡	Former, <3yr	33 / 277	.79 (.52, 1.21)
	Current <3yr	32 / 282	.86 (.54, 1.36)
	Former 3+yr	12 / 96	.96 (.50, 1.86)
	Current, 3+ yr	79 / 844	.81 (.57, 1.15)

^*Includes women who used ET before or after CHT

^†Includes women who used CHT before or after ET

^‡Includes all who used CHT, ET, or both